Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial - 30/06/16
, Scott N Gettinger, MD a, Amit Mahajan, MD a, Anne C Chiang, MD a, Roy S Herbst, ProfMD a, Mario Sznol, ProfMD a, Apostolos John Tsiouris, MD b, Justine Cohen, DO a, Alexander Vortmeyer, MD a, Lucia Jilaveanu, MD a, James Yu, MD a, Upendra Hegde, MD c, Stephanie Speaker, BA a, Matthew Madura, BS a, Amanda Ralabate, BSN a, Angel Rivera, MS a, Elin Rowen, MSN a, Heather Gerrish, BSN a, Xiaopan Yao, PhD a, Veronica Chiang, MD a, Harriet M Kluger, ProfMD aSummary |
Background |
Immunotherapy targeting the PD-1 axis has activity in several tumour types. We aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients with untreated brain metastases from melanoma or non-small-cell lung cancer (NSCLC).
Methods |
In this non-randomised, open-label, phase 2 trial, we enrolled patients aged 18 years or older with melanoma or NSCLC with untreated brain metastases from the Yale Cancer Center. Patients had at least one untreated or progressive brain metastasis between 5 and 20 mm in diameter without associated neurological symptoms or the need for corticosteroids. Patients with NSCLC had tumour tissue positive for PD-L1 expression; this was not required for patients with melanoma. Patients were given 10 mg/kg pembrolizumab every 2 weeks until progression. The primary endpoint was brain metastasis response assessed in all treated patients. The trial is ongoing and here we present an early analysis. The study is registered with ClinicalTrials.gov, number NCT02085070.
Findings |
Between March 31, 2014, and May 31, 2015, we screened 52 patients with untreated or progressive brain metastases (18 with melanoma, 34 with NSCLC), and enrolled 36 (18 with melanoma, 18 with NSCLC). A brain metastasis response was achieved in four (22%; 95% CI 7–48) of 18 patients with melanoma and six (33%; 14–59) of 18 patients with NSCLC. Responses were durable, with all but one patient with NSCLC who responded showing an ongoing response at the time of data analysis on June 30, 2015. Treatment-related serious and grade 3–4 adverse events were grade 3 elevated aminotransferases (n=1 [6%]) in the melanoma cohort, and grade 3 colitis (n=1 [6%]), grade 3 pneumonitis (n=1 [6%]), grade 3 fatigue (n=1 [6%]), grade 4 hyperkalemia (n=1 [6%]), and grade 2 acute kidney injury (n=1 [6%]) in the NSCLC cohort. Clinically significant neurological adverse events included transient grade 3 cognitive dysfunction and grade 1–2 seizures (n=3 [17%]) in the melanoma cohort.
Interpretation |
Pembrolizumab shows activity in brain metastases in patients with melanoma or NSCLC with an acceptable safety profile, which suggests that there might be a role for systemic immunotherapy in patients with untreated or progressive brain metastases.
Funding |
Merck and the Yale Cancer Center.
Le texte complet de cet article est disponible en PDF.Plan
Vol 17 - N° 7
P. 976-983 - juillet 2016 Retour au numéro
Article précédent
- Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database
- Daniel P Nussbaum, Christel N Rushing, Whitney O Lane, Diana M Cardona, David G Kirsch, Bercedis L Peterson, Dan G Blazer
- Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello, James R Rigas, Allison Upalawanna, Anthony M D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E Johnson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?